Nguyen Dao M, Hussain Mustafa
Section of Thoracic Oncology, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Room 4W-4-3940, 10 Center Drive, Bethesda, MD 29892, USA.
J Bioenerg Biomembr. 2007 Feb;39(1):13-21. doi: 10.1007/s10863-006-9055-9.
Optimal cytotoxic anticancer therapy, at the cellular level, requires effective and selective induction of cell death to achieve a net reduction of biomass of malignant tissues. Standard cytotoxic chemotherapeutics have been developed based on the observations that mitotically active cancer cells are more susceptible than quiescent normal cells to chromosomal, microtubular or metabolic poisons. More recent development of molecularly targeted drugs for cancer focuses on exploiting biological differentials between normal and transformed cells for selective eradication of cancers. The common thread of "standard" and "novel" cytotoxic drugs is their ability to activate the apoptosis-inducing machinery mediated by mitochondria, also known as the intrinsic death signaling cascade. The aim of this article is to provide an overview of the role of the mitochondria, an energy-generating organelle essential for life, in mediating death when properly activated by cytotoxic stresses.
在细胞水平上,最佳的细胞毒性抗癌疗法需要有效且选择性地诱导细胞死亡,以实现恶性组织生物量的净减少。标准细胞毒性化疗药物是基于有丝分裂活跃的癌细胞比静止的正常细胞对染色体、微管或代谢毒物更敏感这一观察结果而开发的。癌症分子靶向药物的最新进展集中在利用正常细胞和转化细胞之间的生物学差异来选择性根除癌症。“标准”和“新型”细胞毒性药物的共同特点是它们激活由线粒体介导的凋亡诱导机制的能力,也称为内在死亡信号级联反应。本文旨在概述线粒体(生命必需的能量产生细胞器)在被细胞毒性应激适当激活时介导死亡的作用。